NSEDisclosure of material issue1d ago · 21 Sept 2026, 03:08 pm

Disclosure of material issue

Anlon Healthcare Limited · AHCL

✦ AI SummaryM&A

Anlon Healthcare Limited has informed about the incorporation of its subsidiary, Anlon Healthcare Nigeria Limited, as per Regulation 30 of SEBI Listing Regulations.

Analysis Scores

Earnings Impact5/10
Growth Catalyst8/10
Governance Concern2/10
Regulatory Risk4/10
Balance Sheet Risk6/10
Liquidity Impact8/10
Market Sentiment6/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Anlon Healthcare Limited has informed regarding Disclosure of material issue

Attachments (1)

📄

ANLON2013_21092026150829_AHLIntimationforIncorporationofSubsidiarySigned.pdf

pdf

Download →
View document text
September 21, 2026 To, To, Listing Department, The National Stock Exchange of India BSE Limited Ltd. Phiroze Jeejeebhoy Towers, The Listing Department Dalal Street, Exchange Plaza, Mumbai – 400 001 Bandra – Kurla Complex, Ref: BSE Scrip Code: 544497 Mumbai – 400051, NSE Scrip Code: AHCL Sub: Intimation under Regulation 30 of Securities and Exchange Board of India ("SEBI”) (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") – Incorporation of Subsidiary. Respected Sir/Madam, Pursuant to regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 (“SEBI Master Circular”), we wish to inform you that “ANLON HEALTHCARE NIGERIA LIMITED” having Registration Number “9874492” has been incorporated as a subsidiary of the Anlon Healthcare Limited (“Company”), with effect from September 20, 2026. The relevant details pursuant to Schedule III of the Listing Regulations and additional details as required under the SEBI Master Circular for compliance with the provisions of the Listing Regulations by listed entities is annexed in Annexure – A. You are requested to take the above information on your record. Thanking You. For ANLON HEALTHCARE LIMITED PUNITKUMAR RASADIA MANAGING DIRECTOR DIN: 06696258 ANLON HEALTHCARE LIMITED CIN No.: L24230GJ2013PLC077543 REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot- 360005, Gujarat (INDIA) PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in ANNEXURE-A Details required under Regulation 30 of SEBI LODR read with HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 Sr Particulars Description 1 Name of the target entity, country of Name of the Entity: ANLON incorporation, details in brief such as size, HEALTHCARE NIGERIA LIMITED. turnover etc. Country of Incorporation: NIGERIA Turnover: Nil as the company is the newly incorporated company Size of the Company: Company is incorporated with authorized share capital of Naira 100,000,000 and paid up share capital of Naira 100,000,000. 2 Whether the incorporation of subsidiary Not applicable would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length” 3 Industry to which the entity being Pharmaceuticals, Healthcare, incorporated belongs Personal Care, surgical implants and medical devices 4 Objects and impact of incorporation The purpose of incorporation of this /acquisition (including but not limited to, subsidiary is aligned with the disclosure of reasons for acquisition of Company’s long-term growth target entity, if its business is outside the objective. Considering this main line of business of the listed entity) subsidiary would be manufacturing, importing, processing, producing, trading, packaging, selling, blending ,making of Active Pharmaceutical Ingredients (APIs), pharmaceutical bulk drugs, intermediates and Finished Dosage Formulations for human use, cosmetic and personal care products, surgical implants and medical devices. The Company intends to leverage this opportunity in order to strategically complement and expand its existing business in the West African market. This subsidiary will provide access to 16 Western African Countries via its local entity. 5 Brief details of any governmental or Not Applicable regulatory approvals required for the incorporation/ acquisition ANLON HEALTHCARE LIMITED CIN No.: L24230GJ2013PLC077543 REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot- 360005, Gujarat (INDIA) PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in 6 Indicative time period for completion of Incorporated on September 20, the acquisition 2026 7 Consideration - whether cash Subscription to the share capital of consideration or share swap or any other the subsidiary is by way of banking form and details of the same channel. 8 Cost of subscription / price at which the Equity shares subscribed by Anlon shares are subscribed Healthcare Limited at an aggregate of Naira. 90,000,000 (NINETY MILLION Naira Only) to subscribe 90,000,000 (Ninety Million) equity shares of face value Naira 1 each (One Naira Only) of the subsidiary company. 9 Percentage of shareholding/ control by 90% of the share capital of ANLON the listed entity and / or number of shares HEALTHCARE NIGERIA LIMITED is allotted held by Anlon Healthcare Limited i.e. 90,000,000 (Ninety Million) equity shares of face value Naira 1 each (One Naira Only) of the subsidiary company. 10 Brief background about the entity This Company has been acquired/ incorporated in terms of incorporated to manufacturing, products/line of business acquired, date importing, processing, producing, of incorporation, history of last 3 years trading, packaging, selling, blending turnover, country in which the acquired ,making of Active Pharmaceutical entity has presence and any other Ingredients (APIs), pharmaceutical significant information (in brief) bulk drugs, intermediates and Finished Dosage Formulations for human use, cosmetic and personal care products, surgical implants and medical devices. In view of the significant growth in this sector in India as well as international markets, the Company propose to leverage this opportunity in order to strategically complement and expand our existing business in the African pharma and healthcare segment. Date of Incorporation: 20/09/2026 Turnover: Not applicable (It is a newly incorporated Company and is yet to commence its business) Country in which the incorporated entity has presence: NIGERIA. ANLON HEALTHCARE LIMITED CIN No.: L24230GJ2013PLC077543 REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot- 360005, Gujarat (INDIA) PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in